Skeletal muscle adaptations in patients with lung cancer: Longitudinal observations from the whole body to cellular level

Abstract

AbstractBackgroundCancer and its treatment can adversely affect skeletal muscle, impacting physical function, treatment response and survival. No studies, however, have comprehensively characterized these muscle adaptations longitudinally in human patients at the cellular level.MethodsWe examined skeletal muscle size and function from the whole body to the sub‐cellular level in 11 patients with non‐small cell lung cancer (NSCLC; 6 male/5 female, mean age 58 ± 3 years) studied over a 2‐month observation period starting during their first cycle of standard of care cancer treatment and in 11 age‐ and sex‐matched healthy controls (HC) without a current or past history of cancer. Biopsies of the vastus lateralis were performed to assess muscle fibre size, contractility and mitochondrial content, along with assessments of physical function, whole muscle size and function, and circulating cytokines.ResultsBody weight, composition and thigh muscle area and density were unaltered over time in patients with NSCLC, while muscle density was lower in patients with NSCLC versus HC (P = 0.03). Skeletal muscle fibre size decreased by 18% over time in patients (all P = 0.02) and was lower than HC (P = 0.02). Mitochondrial fractional area and density did not change over time in patients, but fractional area was lower in patients with NSCLC compared with HC (subsarcolemmal, P = 0.04; intermyofibrillar, P = 0.03). Patients with NSCLC had higher plasma concentrations of IL‐6 (HC 1.40 ± 0.50; NSCLC 4.71 ± 4.22; P < 0.01), GDF‐15 (HC 569 ± 166; NSCLC 2071 ± 1168; P < 0.01) and IL‐8/CXCL8 (HC 4.9 ± 1.8; NSCLC 10.1 ± 6.0; P = 0.02) compared with HC, but there were no changes in inflammatory markers in patients with NSCLC over time. No changes were observed in markers of satellite cell activation or DNA damage in patients and no group differences were noted with HC. Whole‐muscle strength was preserved over time in patients with NSCLC coincident with improved single fibre contractility.ConclusionsThis study is the first to comprehensively examine longitudinal alterations in skeletal muscle fibre size and function in patients with NSCLC and suggests that muscle fibre atrophy occurs during cancer treatment despite weight stability and no changes in conventional clinical measurements of whole body or thigh muscle size over this period.